The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting institutional confidence in the healthcare sector's stability, First Horizon Corp has significantly bolstered its investment in pharmaceutical giant Johnson & Johnson. According to reports, the firm purchased an additional 14,753 shares during the first quarter, marking a 10.4% increase in its position. This acquisition brings First Horizon's total holdings to 156,025 shares, valued at approximately $38.1 million, supported by robust earnings and a positive dividend outlook.
This institutional accumulation occurs as the healthcare industry navigates mixed market dynamics, with JNJ competing for global market share against peers such as Pfizer and Merck. Per market data, the company has demonstrated financial resilience despite persistent legal overhangs regarding talc-related litigation. Analysts have noted that recent dividend hikes continue to attract institutional capital seeking stable yields amidst broader market volatility.
From a technical perspective, JNJ shares closed at $256.98 as of July 10, 2026, after trading between a day low of $255.52 and a high of $261.30. Investors should monitor current support levels near $255 as a key indicator for short-term price action, while keeping an eye on upcoming macroeconomic data that could shift sector sentiment.